Written questions by Anderson.

What steps his Department is taking to help increase awareness of ME symptoms.

We published the final delivery plan (FDP) for myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), on 22 July, which focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.To support healthcare professionals in the diagnosis and management of ME/CFS, as set out in the FDP, the Department of Health and Social Care (DHSC) has worked with NHS England to develop an e-learning programme on ME/CFS for healthcare professionals, with the aim of supporting staff to be able to provide better care and improve patient outcomes. All three sessions, with sessions one and two having universal access, whilst the third session is only available to healthcare professionals, of the e-learning programme are now available at the following link:https://learninghub.nhs.uk/catalogue/mecfselearning?nodeId=7288The Medical Schools Council will promote the NHS England e-learning programme on ME/CFS to all United Kingdom medical schools and will encourage those medical schools to provide undergraduates with direct patient experience of ME/CFS. The General Medical Council (GMC) is the regulator of medical schools, and it is important that education is reenforced at different stages of medical training. Royal colleges play an important role in this. The GMC has included ME/CFS in the content map for the new national exam, so all medical schools will need to teach it as a subject.As outlined in the FDP, we will improve awareness of ME/CFS by launching a public awareness initiative to promote wider awareness and understanding of the condition and support available to people with ME/CFS and their families.DHSC will also engage stakeholders to discuss timely diagnosis and support for children who have ME/CFS and their families, as well as best practice in relation to safeguarding responsibilities. This will be taken forward in parallel with NHS England’s actions on ME/CFS services and neighbourhood multidisciplinary teams for children and young people.Furthermore, as outlined in the FDP, the Department for Education is encouraging the sharing of ME/CFS-specific information with relevant organisations and promoting relevant training and resources to support children and young people.

What steps his department are taking to ensure people have access to adequate counselling support for disability diagnoses.

We want disabled people’s access to, and experience of, healthcare services to be equitable, effective, and responsive to their needs. More people, including those experiencing depression and anxiety associated with a disability, now have better access to counselling support provided through NHS Talking Therapies services. We have increased the number of therapy sessions so that more than 670,000 people completed a course of treatment last year, compared to 567,000 in 2016/17. We plan to expand NHS Talking Therapies still further so that 915,000 people complete a course of treatment by March 2029, with improved effectiveness and quality of services.

What steps he is taking to reduce waiting times for (a) tests, (b) diagnosis and (c) treatment for endometriosis.

Reducing waiting lists, including for gynaecology, is a key part of the Government’s Health Mission. We are committed to putting patients first by ensuring that they are seen on time and that they have the best possible experience of care.At the end of September 2025, the gynaecology waiting list, which includes those waiting for endometriosis treatment, stood at 575,653, with 57.1% of patient pathways waiting less than 18 weeks. This is an improvement from September 2024 where the waiting list stood at 587,887, of which 54.6% of patient pathways were waiting less than 18 weeks.Patients waiting for an endometriosis diagnosis may receive diagnostic tests such as magnetic resonance imaging (MRI) and ultrasound, though the only definitive way to diagnose endometriosis is by a laparoscopic procedure. The laparoscopy is also used to treat endometriosis.We will transform diagnostic services and are taking steps to support the National Health Service to increase diagnostic capacity to meet the demand for diagnostic services, including for MRI and ultrasound. This includes expanding existing community diagnostic centres (CDCs), as well as building up to five new ones in 2025/26. The plan also commits to CDCs opening 12 hours per day, seven days a week, delivering more same-day tests and consultations.We are taking action to ensure that individuals with endometriosis not only receive a timely diagnosis but also receive timely and effective treatment.NHS surgical hubs, funded by the Targeted Investment Fund, are specifically designed to deliver high-volume, low-complexity elective surgeries, including gynaecological procedures. These explicitly include operative laparoscopies, endometrial ablation, hysteroscopies, and laparoscopic hysterectomies. As of November 2025, over half of the 123 operational elective surgical hubs in England provide gynaecology services, and laparoscopies are a key part of this offering.The 2025 Spending Review also confirmed over £6 billion of additional capital investment over five years across new diagnostic, elective, and urgent care capacity. This will ensure that we are able to meet women’s health needs and address the challenges across the entirety of patient pathways.

What assessment he has made of the potential merits of increasing levels of research into the (a) causes of and (b) treatment pathways for endometriosis.

The National Institute for Health and Care Research (NIHR), the research delivery arm of the Department, funds and supports a range of research to support women’s health conditions, including endometriosis. These awards seek to improve outcomes for women with endometriosis by better understanding the condition, enabling earlier diagnosis, and evaluating current and emerging treatment options. Ongoing NIHR funded research includes a £2.1 million trial to look at the effectiveness of keyhole surgery to treat endometriosis, with a new £2.4 million NIHR funded research programme on pain management for endometriosis due to start in March 2026. Further information on both of these studies is available, respectively, at the following two links: https://fundingawards.nihr.ac.uk/award/NIHR129801 https://fundingawards.nihr.ac.uk/award/NIHR169738 The NIHR continues to welcome funding applications for research into endometriosis. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

What steps he is taking to increase awareness of endometriosis amongst medical professionals.

In November 2024 the National Institute for Health and Care Excellence updated their guideline on endometriosis to make firmer recommendations for healthcare professionals on referral and investigations for women with a suspected diagnosis. This will help women receive a diagnosis and effective treatment faster. This guideline is available at the following link:https://www.nice.org.uk/guidance/NG73)www.nice.org.uk/guidance/NG73Additionally, the General Medical Council has introduced the Medical Licensing Assessment to encourage a better understanding of common women’s health problems among all doctors as they start their careers in the United Kingdom. The content for this assessment includes several topics relating to women’s health, including endometriosis. This will encourage a better understanding of common women’s health problems among all doctors as they start their careers in the UK.Endometriosis is also included in the core curriculum for trainee general practitioners, and for obstetricians and gynaecologists.

What assessment he has made of the adequacy of care for patients with endometriosis.

The Government recognises the challenges faced by women with endometriosis and the impact it has on their lives, their relationships, and their participation in education and the workforce.In November 2024, the National Institute for Health and Care Excellence (NICE) updated their guideline on endometriosis to makes firmer recommendations for healthcare professionals on referral and investigations for women with a suspected diagnosis and will help the estimated one in ten women with endometriosis to receive a diagnosis faster. Over the next year, NICE will be working with National Health Service systems to ensure adoption of this best practice endometriosis care, including access to approved medicines.Through the National Institute for Health and Care Research (NIHR), we have commissioned a number of studies focused on endometriosis diagnosis, treatment, and patient experience. At present, the NIHR is funding six research awards totalling an investment of approximately £5.8 million.Alongside the updated guidelines and research investment, two new treatments have been approved, and we are taking action to cut gynaecology waiting lists through our Elective Reform Plan.But we know there is more to do. That is why we are renewing the Women’s Health Strategy, to update on delivery and set out how the Government is taking further steps to improve women’s health as we deliver the 10-Year Health Plan. It will also address gaps from the 2022 strategy and drive further changes on enduring challenges such as creating a system that listens to women, and tackling health inequalities.

What recent assessment he has made of the potential impact of increasing drug prices on patients.

No such assessments have been published. We will always prioritise the needs of National Health Service patients, and we are protecting the NHS with record investment and reform to deliver better health care.Investing in the newest medicines so that patients can get access to life saving treatments is a critical part of a modern health care system and one that many charities and patient groups frequently call for.Life sciences are a cornerstone of our modern industrial strategy, driving growth through world-class research, advanced manufacturing, and innovation.

How many tests for spiking were conducted in hospitals in England in each of the last five years.

The requested data is not collected centrally. NHS England does not routinely collect hospital admissions data specifically related to spiking, nor the number of tests conducted explicitly labelled as being for spiking in hospitals.The Home Office has published public guidance for victims and witnesses of spiking, and a statutory report setting out measures to tackle spiking including training for door staff, research into testing, and coordinated policing. The guidance signposts victims to emergency medical care, police reporting, and victim support services. This information is available at the following link:https://www.gov.uk/guidance/spiking-advice-and-support

What recent assessment he has made of the adequacy of (a) testing and (b) support in hospitals for victims of spiking.

The requested data is not collected centrally. NHS England does not routinely collect hospital admissions data specifically related to spiking, nor the number of tests conducted explicitly labelled as being for spiking in hospitals.The Home Office has published public guidance for victims and witnesses of spiking, and a statutory report setting out measures to tackle spiking including training for door staff, research into testing, and coordinated policing. The guidance signposts victims to emergency medical care, police reporting, and victim support services. This information is available at the following link:https://www.gov.uk/guidance/spiking-advice-and-support

What assessment he has made of the potential merits of offering CT scans to former miners.

No assessment has been made on the potential merits of offering computed tomography (CT) scans to former miners. As set out in the recently published Men’s Health Strategy for England, we will expand the existing Respiratory Pathways Transformation Fund initiative by investing an additional £1 million this year through the Oxfordshire Health Innovation Network to develop targeted case-finding initiatives in former coalfield areas, such as those with chronic obstructive pulmonary disease. This will help us to identify the individuals who need support to access appropriate local services. Investigations such as CT scans will be considered for those reporting symptoms in areas in which we are targeting support, if clinically appropriate.

What steps he is taking to reduce the time taken to diagnose Parkinson's.

We recognise the importance of a timely diagnosis of Parkinson’s disease and remain committed to delivering the National Health Service constitutional standard for 92% of patients to wait no longer than 18 weeks from Referral to Treatment by March 2029. We are investing in additional capacity to deliver appointments to help bring lists and waiting times down. Our Elective Reform Plan, published in January 2025, sets out the specific productivity and reform efforts needed to return to the constitutional standard.By expanding community-based services for routine monitoring and follow-up, employing artificial intelligence for productivity and investing in digital tools and data, as outlined in the 10-Year Health Plan, we can ensure that consultants’ time is reserved for complex cases, including specialist diagnostic assessments, which are critical for people with suspected Parkinson’s.Integrated care boards (ICBs) are responsible for commissioning services that meet the needs of their population, including for Parkinson’s. In doing so, the Government expects ICBs to take account of the relevant guidelines and best practice in designing their local services. The National Institute for Health and Care Excellence guideline on Parkinson’s disease (NG71) states that people with Parkinson’s should have an accessible point of contact with specialist services, which can be provided by a Parkinson’s nurse specialist, and that all individuals should be offered access to the services provided by these specialist nurses to support ongoing care and advice.The guideline is available at the following link:https://www.nice.org.uk/guidance/ng71We acknowledge the significant neurology workforce challenges across the country, including the need for more specialist nurses. The forthcoming 10 Year Workforce Plan will set out how we will we train and provide the staff, technology, and infrastructure the NHS needs to make it more accessible, proactive, and tailored for all patients, including those with Parkinson’s.

What steps he is taking to increase the number of specialist Parkinson’s nurses.

We recognise the importance of a timely diagnosis of Parkinson’s disease and remain committed to delivering the National Health Service constitutional standard for 92% of patients to wait no longer than 18 weeks from Referral to Treatment by March 2029. We are investing in additional capacity to deliver appointments to help bring lists and waiting times down. Our Elective Reform Plan, published in January 2025, sets out the specific productivity and reform efforts needed to return to the constitutional standard.By expanding community-based services for routine monitoring and follow-up, employing artificial intelligence for productivity and investing in digital tools and data, as outlined in the 10-Year Health Plan, we can ensure that consultants’ time is reserved for complex cases, including specialist diagnostic assessments, which are critical for people with suspected Parkinson’s.Integrated care boards (ICBs) are responsible for commissioning services that meet the needs of their population, including for Parkinson’s. In doing so, the Government expects ICBs to take account of the relevant guidelines and best practice in designing their local services. The National Institute for Health and Care Excellence guideline on Parkinson’s disease (NG71) states that people with Parkinson’s should have an accessible point of contact with specialist services, which can be provided by a Parkinson’s nurse specialist, and that all individuals should be offered access to the services provided by these specialist nurses to support ongoing care and advice.The guideline is available at the following link:https://www.nice.org.uk/guidance/ng71We acknowledge the significant neurology workforce challenges across the country, including the need for more specialist nurses. The forthcoming 10 Year Workforce Plan will set out how we will we train and provide the staff, technology, and infrastructure the NHS needs to make it more accessible, proactive, and tailored for all patients, including those with Parkinson’s.

What steps he is taking to reduce wait times to see a neurologist.

Cutting waiting lists is a key priority for the Government. We have exceeded our pledge to deliver an extra two million operations, scans, and appointments, having delivered 5.2 million more appointments across elective care services. This marks a vital first step to delivering on the commitment that 92% of patients will wait no longer than 18 weeks from referral to consultant-led treatment, in line with the National Health Service constitutional standard, by March 2029.Between September 2024 and 2025, we reduced the number of incomplete neurology pathways by over 15,000, from 234,720 to 219,221, and reduced the average waiting time for neurology services from 16.2 to 15.2 weeks. 57.2% of patients referred were waiting within 18 weeks, up from 54% at the same point last year. This is still lower than the national average and we are continuing efforts to improve this, recognising that this is a challenged specialty.The January 2025 Elective Reform Plan commits to reforming outpatient services, including by supporting general practitioners and hospital doctors to work better together to ensure referrals are used only when a patient really needs hospital care, through increased uptake of Advice and Guidance. There are a number of initiatives at the national level supporting service improvement and better care for patients with neurological conditions, including the United Kingdom-wide Neuro Forum, RightCare Progressive Neurological Conditions Toolkit, and the Getting It Right First Time Programme for Neurology.

What steps his Department is taking to support research into motor neurone disease.

Government responsibility for delivering research into motor neurone disease (MND) is shared between the Department of Health and Social Care, with research delivered via the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation, and Technology, with research delivered via UK Research and Innovation (UKRI) and the Medical Research Council for MND.The Government is investing in MND research across a range of areas, including an £8 million investment via the NIHR into the EXPERTS-ALS. This is a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis (ALS): the most common form of MND.The MND Translational Accelerator, supported by £6 million of Government funding, is connecting the UK Dementia Research Institute, the UK MND Research Institute and Dementias Platform UK. Twelve projects have been funded through the Accelerator; all aimed at speeding up the development of treatments for MND.The NIHR and UKRI continue to welcome funding applications for research into MND.

What discussions he has had with private social care providers on levels of challenges for their staff.

I regularly hold discussions with providers from across the social care sector, including private and voluntary sectors, and with local authority providers. This includes roundtables and site visits.Department officials also regularly engage with private adult social care providers and sector representatives to understand the challenges faced by their workforce.In order to gain a full understanding of issues affecting the workforce, the Department commissioned ‘The Adult Social Care workforce and their work-related quality of life survey’ which provides detailed evidence on the issues most affecting staff.The full survey report is available at the following link:https://www.gov.uk/government/publications/adult-social-care-asc-workforce-and-work-related-quality-of-life

What steps he is taking to support social care staff working in supported living accommodation.

The Government recognises the vital role of social care staff working in supported living accommodation in enabling people to live independently with dignity.We are committed to transforming adult social care and supporting adult social care workers, turning the page on decades of low pay and insecurity. That is why we plan to introduce the first ever Fair Pay Agreement in 2028, backed by £500 million of funding to improve pay and conditions for the adult social care workforce. This will improve recruitment and retention and give staff better recognition for their vital work. The £500 million forms part of an increase of over £4 billion of additional funding available for adult social care in 2028-29, compared to 2025-26.Ensuring staff have the skills and training needed to work in social care is also essential, both to attract people to join and remain in the workforce, and for the provision of high-quality care and support. That is why we have developed the Care Workforce Pathway, the first national career framework for adult social care, and, we are investing £12 million in learning and development through the Learning and Development Support Scheme, to enable eligible staff to complete eligible courses and qualifications.These actions form part of our wider commitment to improving skills and support for the social care workforce.

What steps he is taking to improve care for people with motor neurone disease.

NHS England commissions the specialised elements of motor neurone disease (MND) care that patients may receive from 27 specialised neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals and specialised treatment and support, according to their needs. At the national level, there are a number of initiatives supporting service improvement and better care for patients with MND, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit. NHS England has also established a Neurology Transformation Programme, a multi-year, clinically-led programme, which has developed a new model of integrated care to support integrated care boards to deliver the right service, at the right time for all neurology patients, including those with MND. In August 2025, NHS England updated its service specification for specialised adult neurology services. The service specification outlines that specialised neurology centres must include services for neuromuscular disorders, including MND. Service specifications define the standards of care expected from organisations funded by NHS England to provide specialised care.

What steps he is taking to help improve access to affordable home adaptations for people with motor neurone disease.

We recognise how important the right housing arrangements are in supporting people to live as independently and safely as possible. In England, we continue to fund the Disabled Facilities Grant (DFG), which is administered by local authorities. This grant helps eligible older and disabled people on low incomes, including people with motor neurone disease, to adapt their homes.We have provided an additional £172 million over this and the last financial year to uplift the DFG. This uplift could provide approximately 15,600 extra home adaptations to give people more independence in their homes. This brings the total funding for the DFG to £711 million in each of 2024/25 and 2025/26.

If he will make an assessment of the adequacy of systems for determining the duration of NHS funding for anticancer agents.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.

What steps his Department is taking to help ensure that people who cannot afford anticancer treatment will continue to receive treatment beyond the stopping date of their anticancer agent being available on the NHS.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussionThe Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.